NCT04277624View on ClinicalTrials.gov

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

February 21, 2021

Study Completion Date

February 26, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

fezolinetant - test formulation

Administered orally

DRUG

fezolinetant - reference formulation

Administered orally

Trial Locations (1)

21225

PAREXEL Early Phase Clinical Unit, Baltimore

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04277624 - A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants | Biotech Hunter | Biotech Hunter